NBIX
Neurocrine Biosciences, Inc.
Halal Rating :
Last Price
$143.20
Last updated:
Market Cap
-
7D Change
0.12%
1 Year Change
2.43%
Company Overview
Industries
Exchange
Next Earnings Date
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on developing treatments for neurological, endocrine, and psychiatric disorders. The company's primary revenue comes from INGREZZA, a medication for tardive dyskinesia, and ORILISSA, used for managing endometriosis pain. They also have several other products in their pipeline targeting various neurological and endocrine conditions.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $622.1m | $438.3m | - | - | 0.00% | 0.00% |
| June 30, 2024 | $590.2m | $494.5m | - | $49.7m | 0.00% | 10.05% |
| March 31, 2024 | $515.3m | $417.1m | - | $1.1m | 0.00% | 0.26% |
Company Impact
Help us evaluate Neurocrine Biosciences, Inc.'s impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.